- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT07792928
A Phase 1 Study to Evaluate the Safety and Effects of a Single Dose of HCXT-2001 Tablets and HCXT-2001 Tablets(A) in Healthy Adults.
25 de agosto de 2026 actualizado por: Shanghai Peptidstar Therapeutics Limited
A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of HCXT-2001 Tablets and HCXT-2001 Tablets(A) After Single Administration in Healthy Adult Participants.
The goal of this intervention study is to assess the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of HCXT-2001 Tablets and HCXT-2001 Tablets(A) in Healthy Participants.
The main parameters it aims to answer are: Does a single dose of HCXT-2001 Tablets and HCXT-2001 Tablets(A) in healthy participants impact the Safety, Tolerability, Pharmacokinetics, and Immunogenicity profiles?
This study will be a - randomized, double blind, placebo-controlled study.
Descripción general del estudio
Estado
Aún no reclutando
Condiciones
Tipo de estudio
Intervencionista
Inscripción (Estimado)
40
Fase
- Fase 1
Contactos y Ubicaciones
Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.
Estudio Contacto
- Nombre: Laura E Elliot, MBCHb
- Número de teléfono: +64 9 242 3321
- Correo electrónico: laura.elliott@momcr.co.nz
Ubicaciones de estudio
-
-
Auckland
-
Takapuna, Auckland, Nueva Zelanda, 0622
- Momentum Clinical Research (MCR)
-
Contacto:
- Laura E Elliot, MBCHb
- Número de teléfono: +64 9 242 3321
- Correo electrónico: laura.elliott@momcr.co.nz
-
-
Criterios de participación
Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.
Criterio de elegibilidad
Edades elegibles para estudiar
- Adulto
Acepta Voluntarios Saludables
Sí
Descripción
Inclusion Criteria:
- Body weight ≥ 50 kg for males and ≥ 45 kg for females, and body mass index (BMI) between 18.0 and 30.0 kg/m2 (inclusive) at screening.
- In good general health as determined by medical history, vital signs, physical examination, 12-lead ECG, laboratory tests (including hematology, blood biochemistry, coagulation function tests, urinalysis, stool routine tests), chest X-ray, etc., with results either within normal limits or assessed by the investigator as not clinically significant.
- Has been fully informed about the study, voluntarily agrees to participate, and has signed the ICF.
- The participant and their sexual partner(s) have no plans for conception from 2 weeks before screening until 6 months after the last dose of the investigational product, and agree to voluntarily using one or more highly effective non-pharmacological contraceptive methods and no intention of donating sperm or eggs during this period.
Exclusion Criteria:
- History or presence of immunological diseases.
- Women who are pregnant or are breastfeeding.
- Any prior or current disease or abnormality that, in the investigator's judgment, is clinically significant and may interfere with the conduct or interpretation of the study, including but not limited to neurological, cardiovascular, renal, hepatic, gastrointestinal, respiratory, hematological, endocrine, oncologic, pulmonary, immunological, psychiatric, or cerebrovascular conditions.
- Individuals who smoked, consumed coffee, St. John's Wort (hypericum perforatum), grapefruit, pomelo juice, or cranberry juice, and/or engagement in strenuous physical activity within 24 hours prior to dosing, which in the opinion of the investigator may affect drug absorption, distribution, metabolism, or excretion.
- Suspected or known allergy to any component of the investigational product, or any documented history of allergies
- Previous surgical procedures that may affect the results of the clinical study or gastric/abdominal surgery that may impact oral drug absorption; or recent major gastric/abdominal surgery of any kind within 12 weeks prior to screening or during study. With the exception of minor surgeries that in the opinion of the investigator/medical monitor, such as excision of subcutaneous lipomas.
- Having taken any prescription medication, over-the-counter drug, herbal medicine, or dietary supplement within 14 days prior to dosing or within five half-lives of the first administration, except for the condition without impact on the study outcomes as determined by the investigator. Occasional paracetamol less than 1000 mg for minor ailments is permitted if required.
- Non-physiological blood loss or donation of more than 400 mL of blood within 2 months prior to screening, receipt of a blood transfusion within 2 months prior to screening; or plans to donate blood during the study or within 60 days after the last dose.
- Participation in any investigational drug or medical device clinical trial with administration of the investigational product or device intervention within 3 months or five half-lives prior to screening.
- History of alcohol abuse, or consumption of more than 14 alcohol units per week within 6 months prior to screening , or unwillingness to abstain from alcohol during the study, or a positive alcohol test at screening.
- History of smoking (average daily cigarette consumption ≥ 5 cigarettes within 3 months prior to screening) or unwillingness to abstain from smoking during the study.
- History of drug abuse, use of illicit drugs within 3 months prior to the study, or a positive urine drug screen.
- Infection (including chronic or localized infection) within 7 days prior to screening, or a history of recurrent infections with underlying conditions predisposing to infections, or a history of opportunistic infections.
- Positive test result for any of the following: hepatitis B surface antigen, syphilis-specific antibody, hepatitis C antibody, or human immunodeficiency virus antibody.
- Those who have received any vaccine within 1 month prior to screening, or who are scheduled to receive any vaccine during the study or within 1 month after study completion.
- Having any other factors that, in the opinion of the investigator, may affect the study results or interfere with the participant's participation in the clinical study.
Plan de estudios
Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación de un solo grupo
- Enmascaramiento: Cuadruplicar
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: HCXT-2001 Tablets - Cohort 1
|
Two tablets taken orally in a fasted state
One tablet taken orally in a fasted state
|
|
Experimental: HCXT-2001 Tablets - Cohort 2
|
Two tablets taken orally in a fasted state
One tablet taken orally in a fasted state
|
|
Comparador de placebos: HCXT-2001 Tablets - Placebo Cohort 1
|
Two tablets taken orally in a fasted state
One tablet taken orally in a fasted state
|
|
Experimental: HCXT-2001 Tablets(A) - Cohort 3
|
Two tablets taken orally in a fasted state
One tablet taken orally in a fasted state
|
|
Experimental: HCXT-2001 Tablets(A) - Cohort 4
|
Two tablets taken orally in a fasted state
One tablet taken orally in a fasted state
|
|
Comparador de placebos: HCXT-2001 Tablets(A) - Placebo Cohort 3
|
Two tablets taken orally in a fasted state
One tablet taken orally in a fasted state
|
|
Comparador de placebos: HCXT-2001 Tablets - Placebo Cohort 2
|
Two tablets taken orally in a fasted state
One tablet taken orally in a fasted state
|
|
Comparador de placebos: HCXT-2001 Tablets(A) - Placebo Cohort 4
|
Two tablets taken orally in a fasted state
One tablet taken orally in a fasted state
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Periodo de tiempo |
|---|---|
|
Number of participants with AEs,SEAs, with abnormal - vital signs,physcial examinations,clinical laboratory results ,12-lead ECGs and stool routine tests
Periodo de tiempo: Day 1 to Day 50
|
Day 1 to Day 50
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Maximum concentration of the drug (Cmax) following a single oral dose of HCXT-2001 tablets and HCXT-2001 tablets(A).
Periodo de tiempo: Day 1 to Day 50
|
Will be calculated using the non-compartmental analysis.
|
Day 1 to Day 50
|
|
Time to maximum concentration (Tmax) following a single oral dose of HCXT-2001 tablets and HCXT-2001 tablets(A).
Periodo de tiempo: Day 1 to Day 50
|
Will be calculated using the non-compartmental analysis.
|
Day 1 to Day 50
|
|
Area under the plasma concentration-time curve (AUC, including AUC0-t and AUC0-inf, etc.) following a single oral dose of HCXT-2001 tablets and HCXT-2001 tablets(A).
Periodo de tiempo: Day 1 to Day 50
|
Will be calculated using the non-compartmental analysis.
|
Day 1 to Day 50
|
|
Apparent volume of distribution (Vd/F) following a single oral dose of HCXT-2001 tablets and HCXT-2001 tablets(A).
Periodo de tiempo: Day 1 to Day 50
|
Will be calculated using the non-compartmental analysis.
|
Day 1 to Day 50
|
|
Apparent clearance (CL/F) following a single oral dose of HCXT-2001 tablets and HCXT-2001 tablets(A)
Periodo de tiempo: Day 1 to day 50
|
Will be calculated using the non-compartmental analysis.
|
Day 1 to day 50
|
|
Plasma elimination half-life (t1/2) following a single oral dose of HCXT-2001 tablets and HCXT-2001 tablets(A).
Periodo de tiempo: Day 1 to Day 50
|
Will be calculated using the non-compartmental analysis.
|
Day 1 to Day 50
|
|
Mean residence time (MRT) following a single oral dose of HCXT-2001 tablets and HCXT-2001 tablets(A).
Periodo de tiempo: Day 1 to Day 50
|
Will be calculated using the non-compartmental analysis.
|
Day 1 to Day 50
|
|
Anti-drug antibodies (ADAs) following a single oral dose of HCXT-2001 tablets and HCXT-2001 tablets(A).
Periodo de tiempo: Day 1 to Day 50
|
Day 1 to Day 50
|
|
|
Neutralizing antibodies (Nabs) following a single oral dose of HCXT-2001 tablets and HCXT-2001 tablets(A).
Periodo de tiempo: Day 1 to Day 50
|
Day 1 to Day 50
|
Colaboradores e Investigadores
Aquí es donde encontrará personas y organizaciones involucradas en este estudio.
Patrocinador
Colaboradores
Fechas de registro del estudio
Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.
Fechas importantes del estudio
Inicio del estudio (Estimado)
14 de agosto de 2026
Finalización primaria (Estimado)
10 de noviembre de 2026
Finalización del estudio (Estimado)
10 de noviembre de 2026
Fechas de registro del estudio
Enviado por primera vez
25 de agosto de 2026
Primero enviado que cumplió con los criterios de control de calidad
25 de agosto de 2026
Publicado por primera vez (Actual)
28 de agosto de 2026
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
28 de agosto de 2026
Última actualización enviada que cumplió con los criterios de control de calidad
25 de agosto de 2026
Última verificación
1 de julio de 2026
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- HCXT-2001-PS-1-02
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
No
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
No
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .